High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer
Urologic Oncology: Seminars and Original Investigations | Dec 08, 2017
Urologic Oncology: Seminars and Original Investigations | Dec 08, 2017